Unresectable melanoma Stage IIIC and Stage IV BRAF V600E
Showing 1 - 25 of >10,000
Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 Trial
Active, not recruiting
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- +4 more
- Dabrafenib Mesylate
- +3 more
-
Philadelphia, PennsylvaniaPerelman Center for Advanced Medicine
Dec 29, 2021
BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Malignant Solid Tumor Trial in Boston (Dabrafenib,
Active, not recruiting
- BRAF V600E Mutation Present
- +9 more
- Dabrafenib
- +4 more
-
Boston, Massachusetts
- +1 more
Jun 28, 2022
Metastatic Melanoma Trial in Darlinghurst, Sydney, Brisbane (Palliative radiotherapy, Dabrafenib and trametinib (combination))
Completed
- Metastatic Melanoma
- Palliative radiotherapy
- Dabrafenib and trametinib (combination)
-
Darlinghurst, New South Wales, Australia
- +2 more
Apr 6, 2022
Melanoma Trial in Louisville (Vemurafenib, Metformin)
Recruiting
- Melanoma
-
Louisville, KentuckyJames Graham Brown Cancer Center-University of Louisville
Oct 22, 2021
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID
Active, not recruiting
- Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
- +2 more
- Dabrafenib
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Aug 9, 2022
Aspirin in Combination With Trametinib and Dabrafenib
Not yet recruiting
- NSCLC
- +4 more
- Combind asprin with Trametinib and Dabrafenib
- (no location specified)
Aug 4, 2023
Metastatic Malignant Tumor in the Brain, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7 Trial in Houston (drug,
Active, not recruiting
- Metastatic Malignant Neoplasm in the Brain
- +7 more
- Binimetinib
- +6 more
-
Houston, TexasM D Anderson Cancer Center
Jun 15, 2022
Clinical Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous
Recruiting
- Clinical Stage III Cutaneous Melanoma AJCC v8
- +5 more
- Atezolizumab
- +3 more
-
Jacksonville, Florida
- +2 more
Oct 21, 2022
Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7 Trial in Rochester (drug,
Active, not recruiting
- Metastatic Melanoma
- +6 more
- Ibrutinib
- +2 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 13, 2023
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma
Terminated
- Metastatic Colon Adenocarcinoma
- +27 more
- Binimetinib
- +3 more
-
San Francisco, California
- +1 more
Jan 5, 2023
Malignant Melanoma, Metastatic Melanoma, Immunotherapy Trial (Pembrolizumab, Encorafenib, Binimetinib)
Not yet recruiting
- Malignant Melanoma
- +4 more
- Pembrolizumab
- +2 more
- (no location specified)
Mar 31, 2022
Liquid Biopsy, Melanoma (Skin), Melanoma Stage III Trial in Rome (Affinity Mediated Transport Amplification (AMT))
Recruiting
- Liquid Biopsy
- +4 more
- Affinity Mediated Transport Amplification (AMT)
-
Rome, Italy"Regina Elena" National Cancer Institute
Jul 13, 2023
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Tumor in the Brain, Metastatic Malignant Tumor in the CNS
Recruiting
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- +3 more
- Dabrafenib
- MEK-1/MEKK-1 Inhibitor E6201
-
Scottsdale, Arizona
- +2 more
Jan 4, 2023
BRAF V600E Unresectable or Metastatic Melanoma, BRAF V600E Metastatic NSCLC, Melanoma Trial in Guangzhou (Encorafenib)
Completed
- BRAF V600E Unresectable or Metastatic Melanoma
- +2 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Jun 9, 2022
Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer, Colorectal Cancer Stage IV Trial in Chicago
Recruiting
- Stage IV Colorectal Cancer Positive for BRAF V600E Mutation
- +2 more
- Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab
-
Chicago, IllinoisNorthwestern University
Nov 16, 2022
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma
Recruiting
- Anatomic Stage IV Breast Cancer AJCC v8
- +20 more
- Neoantigen Peptide Vaccine
- +2 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Sep 7, 2022
Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7 Trial in
Active, not recruiting
- Stage III Cutaneous Melanoma AJCC v7
- +4 more
- Cryosurgery
- +3 more
-
Rochester, MinnesotaMayo Clinic
Jan 3, 2023
Melanoma Trial in Tampa (XL888, Vemurafenib)
Active, not recruiting
- Melanoma
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Aug 18, 2022
Metastatic Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7 Trial in Jacksonville (drug,
Active, not recruiting
- Metastatic Melanoma
- +3 more
- Imiquimod
- +2 more
-
Jacksonville, FloridaMayo Clinic in Florida
Jan 3, 2023
Clinical Stage III Cutaneous Melanoma AJCC v8, Stage IV Melanoma, Unresectable Stage III Cutaneous Melanoma Trial in Boston
Recruiting
- Clinical Stage III Cutaneous Melanoma AJCC v8
- +3 more
-
Boston, Massachusetts
- +2 more
Sep 17, 2022
BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Melanoma Trial in Boston (drug, biological, other)
Terminated
- BRAF V600E Mutation Present
- +7 more
- Dabrafenib
- +4 more
-
Boston, Massachusetts
- +1 more
Mar 9, 2022
Colon Adenocarcinoma, Microsatellite Stable Colon Carcinoma, Stage IIB Colon Cancer AJCC v8 Trial (drug, biological, procedure,
Not yet recruiting
- Colon Adenocarcinoma
- +4 more
- Encorafenib
- +5 more
- (no location specified)
Jan 24, 2023
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous
Active, not recruiting
- Clinical Stage III Cutaneous Melanoma AJCC v8
- +20 more
- Ipilimumab
- +3 more
-
Tampa, Florida
- +6 more
Jan 13, 2023
BRAF NP_004324.2:p.V600X, KRAS wt Allele, Metastatic Malignant Solid Tumor Trial in Houston (biological, drug, other)
Active, not recruiting
- BRAF NP_004324.2:p.V600X
- +6 more
- Cetuximab
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Sep 22, 2022